This study of the academic and pharma/biotech sectors in North America and Europe will provide an analysis of the market for primary cells and an assessment of the brand equity for the leading companies who serve this market. This report will also describe the emerging market for stem cell-derived differentiated cells—a potential threat (or opportunity) for this market.
This study will explore the following market analytics:
- The number of researchers who currently or plan to use primary cells in their research
- Proportion of researchers/labs who purchase primary cells
- Annual lab budget associated with primary cell purchase
- Market size, in terms of revenue, based on 2012
- Supplier share in terms of revenue
- Market growth in terms of revenue in the next 12 months (through 2013)
This study will explore the following product analytics:
- The different types of cells used in life science research
- Motivation for primary cell use
- The motivation for—or barriers preventing—the purchase of primary cells
- The top primary cell types used
- The leading suppliers of primary cells
- Customer satisfaction with primary cell product offerings
- The emerging commercial market for stem cell-derived differentiated cells by customer type, motivation for use, cell types, leading suppliers, and estimated budget
This study will explore the following brand analytics:
- The Brand Share Index for leading primary cell suppliers
- Customer loyalty and likelihood to reorder
With barriers to entry low, the number of companies supplying high quality human tissue for research continues to rise. At the same time, the range of cell types available has also expanded to include more specialized normal cell types as well as cells isolated from non-normal or disease-state tissues. Many primary cell suppliers have also commercialized various types of multipotent stem cells, also called adult stem cells. Like other primary cells, adult stem cells have a finite number of population doublings in vitro. Depending on the cell type used, primary cells and adult stem cells are used in a wide variety of research applications: from basic or discovery research, to drug discovery and development; from ADME/Toxicology screening to regenerative medicine and in vitro tissue models.
In The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities, BioInformatics LLC takes the pulse of this dynamic market. This study seeks to identify where primary cells and primary cell suppliers fit in the universe of cells used in in vitro systems, whether or not the use of primary cells is increasing or decreasing, what cell types are used most often, how satisfied scientists are with commercially available primary cells, and what is the market size and anticipated growth rate.
Stem Cell-Derived Differentiated Cells Pluripotent stem cells—those capable of differentiating into any cell type—have captured the imagination of scientists across many disciplines. As cell culture know-how has evolved, better and more reproducible conditions for maintaining these cells in their pluripotent state have been developed. Concomitant with optimizing cell culture conditions to maintain pluripotency have been efforts to optimize the in vitro environment to induce differentiation to create populations of highly pure and rigorously characterized differentiated cell types, including neurons, cardiomyocytes and hepatocytes.
Because terminally differentiated cells can be used in many applications where primary cells are currently employed and because the concept is relatively new, suppliers are asking multiple questions about this technology. Are researchers responding to the availability of this new source of cells? How many? What cell types are important? Where are they obtained? How will the use of primary cells be affected by the availability of stem cell-derived differentiated cell types? The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities profiles this emerging market and the role of commercial suppliers in this area.